Recruiting
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants - CV028-005
Zaktualizowano: 20 grudzień, 2023 | ClinicalTrials.gov
Etap
Płeć
Zakres wieku
Lokalizacje
Recruiting
Inclusion Criteria: - Has stable primary dilated cardiomyopathy due to either MYH7 or TTN variant - Has adequate acoustic windows for echocardiography - Maximum of 3 family members with same variant can be enrolled Exclusion Criteria: - Significant structural cardiac abnormalities including valvar dysfunction on Screening transthoracic echo(s) - A pathogenic variant implicated in DCM of another gene other than MYH7 or TTN - Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, afterload reduction, or diuretics) - Presence of protocol specified laboratory abnormalities at Screening - Recent acute coronary syndrome or angina pectoris (<90 days) - Recent hospitalization for heart failure (<90 days)
